Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Hisamitsu Posts 2.7% Loss in Mar-Aug Results on Shipping Adjustments of Main Products
October 13, 2011
- Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
- Hisamitsu: Sales of Norspan Lower Than Expected
October 13, 2011
- CHMP Recommends Approval of Novo’s Levemir for Type I Diabetes in Children
October 13, 2011
- Asahi Kasei Pharma to Start Clinical Trials in 2012 of US Transdermal Patch Formulation
October 12, 2011
- NanoCarrier, France’s LFB Agree on Joint Research Agreement
October 12, 2011
- MediciNova Gets Approval for Chinese Joint Venture
October 12, 2011
- PIII Study of Rivaroxaban in Patients with ACS to be Presented at AHA Congress: Bayer
October 12, 2011
- Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
- AZ to Invest $200 Mil. to Build New Factory in China
October 12, 2011
- Merck Receives FDA Approval for Fixed Dose Combination of Januvia, Simvastatin
October 12, 2011
- PACIFIC Study Finds Higher Rate of STEMI in ACS in Japanese
October 12, 2011
- Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
- Sales of Publicly Funded Vaccines Continue to Increase in August: Crecon Research & Consulting
October 11, 2011
- AZ to Reduce US HQ Staff by approx. 400
October 11, 2011
- Results of PIII Trial of Rotarix Published in US Journal Vaccine: GSK
October 10, 2011
- Tsuruha HD to Establish Drugstore Joint Venture in Thailand
October 10, 2011
- Teva, Kowa to Break Up Joint Venture After Just 3 Years
October 10, 2011
- MediciNova Announces Private Sale of Stock to Kissei
October 10, 2011
- Novartis Pharma Donates ¥21 Mil. for Free Medical Exams for Disaster Victims in Soma City
October 10, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…